Evidence map›Paper›PMID 41029436›Full record

ArticleJournal of experimental & clinical cancer research : CR2025

FSTL3 is a biomarker of poor prognosis and associated with immunotherapy resistance in ovarian cancer.

Maeva Chauvin, Estelle Tromelin, Julien Roche-Prellezo, Hyshem H Lancia, Marie-Charlotte Meinsohn, Caroline Coletti, Ngoc Minh Phuong Nguyen, Virginie Lafont, Henri-Alexandre Michaud, Ranjan Mishra and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Maeva Chauvin *Department of Surgery, Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA. MYCHAUVIN@mgh.harvard.edu.
Estelle Tromelin *Department of Surgery, Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Julien Roche-PrellezoDepartment of Surgery, Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Hyshem H LanciaDepartment of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Marie-Charlotte MeinsohnDepartment of Surgery, Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Caroline ColettiDepartment of Surgery, Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Ngoc Minh Phuong NguyenDepartment of Surgery, Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Virginie LafontInstitut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, France.
Henri-Alexandre MichaudInstitut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, France.
Ranjan MishraWhitehead Institute for Biomedical Research, Cambridge, MA, USA.
Nathalie BonnefoyInstitut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, France.
Laurent GrosInstitut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, France.
David PépinDepartment of Surgery, Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA. DPEPIN@mgh.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-grade serous ovarian carcinoma (HGSOC) is associated with high mortality rates due to late-stage diagnosis and limited treatment options. We investigated the role of FSTL3 in ovarian cancer progression both as a prognostic biomarker and as a potential therapeutic target.We measured levels of follistatin (FST) and follistatin-like 3 (FSTL3) in 96 ovarian cancer patient ascites samples and found that FSTL3 overexpression was more predominant than FST and associated with poorer survival outcomes. Mice implanted with an HGSOC syngeneic cell line bearing common alterations in ovarian cancer (KRAS

Indexed as

Biomarkers, TumorDrug Resistance, NeoplasmFollistatin-Related ProteinsImmunotherapyOvarian NeoplasmsAnimalsCell Line, TumorFemaleHumansMicePrognosisTumor MicroenvironmentBiomarkers, TumorFollistatin-Related ProteinsFstl3 protein, human

Identifiers

PMID41029436
PMCPMC12487040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.